Contractor directoryCompany profile
Explore awardsCompareFollowSave company

Federal contractor profile

ROCHE DIAGNOSTICS S.P.A.

UEI CRBLKCZC9XC6CAGE A2592

Active

Overview

Legal name
ROCHE DIAGNOSTICS S.P.A.
Registered location
MONZA, MB, ITA
Primary NAICS
325413 — In-Vitro Diagnostic Substance Manufacturing
Latest award activity
Apr 14, 2026
Read company summary

ROCHE DIAGNOSTICS S.P.A. is associated with UEI CRBLKCZC9XC6 and CAGE A2592 in public federal records. AcornBids currently links 2 prime awards totaling $45.8K in obligations to this entity. Its largest recorded federal customer by obligations is Department of Defense. Its recorded federal awards include work classified as In-Vitro Diagnostic Substance Manufacturing. These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 325413 (In-Vitro Diagnostic Substance Manufacturing). Its public SAM.gov registration lists MONZA, MB, ITA.

At a glance

Lifetime prime obligations$45.8K
Prime awards2
Awards with future end dates0
Top-agency concentration100.0%

Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Oct 6, 2026. Refresh pending; these totals may be out of date.

Business information

Public SAM.gov registration details.

Legal name
ROCHE DIAGNOSTICS S.P.A.
UEI
CRBLKCZC9XC6
CAGE
A2592
Registered address
VIA GIAN BATTISTA STUCCHI 110, MONZA, MB, 20900, ITA
Registration status
Active
Primary NAICS
325413 — In-Vitro Diagnostic Substance Manufacturing
SAM activation
Oct 28, 2025
Initial registration
Mar 18, 2010
Entity start
Sep 27, 1990
SAM updated
Oct 28, 2025
Registration expires
Oct 28, 2026
Fiscal year end
Dec 31

View SAM.gov source

Research brief

Source facts

  • Loaded prime-award records link 2 awards and $45,817 in reported obligations to this legal entity. Source
  • Recorded awards include In-Vitro Diagnostic Substance Manufacturing (NAICS 325413); this classification is not proof of every company capability. Source
  • An example award describes: CLINICAL CHEMISTRY COST PER REPORTABLE RESULT Source

Federal award analysis

Net transaction obligations by federal fiscal period.

Selected transaction obligations$45.8K
Prime contracts
$45.8KFY2026

Reported transaction obligations by federal fiscal period; includes deobligations. Missing transactions are not estimated. Coverage: 2 of 2 selected awards. Select a period to explore its awards.

Explore funding & geography →View quarterly funding

Funding change

Dated, valued transaction obligations in equal-length adjacent periods; missing records are unknown. Default: last completed federal fiscal year. Percentage is unavailable when the prior period has no positive reported obligations.

MeasureReported value
Current periodOct 1, 2025 – Sep 30, 2026
Current obligations$45.8K
Prior periodOct 1, 2024 – Sep 30, 2025
Prior obligationsNot reported
ChangeNot reported
GrowthNot comparable

Where the work is performed

AKMEVTNHWAIDMTNDMNWIMINYMAORNVWYSDIAILINOHPANJCTRICAUTCONEMOKYWVVAMDDEAZNMKSARTNNCSCDCOKLAMSALGAHITXFL

State tile map; darker tiles have larger absolute net obligations. Outlined tiles indicate net deobligations. Unshaded tiles have no reported transactions in this selection. Other locations appear in the table.

Agencies
CategoryPeriod obligationsAwards
Department of Defense$45.8K2
Offices
CategoryPeriod obligationsAwards
DEFENSE HEALTH AGENCY$45.8K2
Naics
CategoryPeriod obligationsAwards
325413 — In-Vitro Diagnostic Substance Manufacturing$45.8K2
Psc
CategoryPeriod obligationsAwards
6550 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets$45.8K2
Vehicles
CategoryPeriod obligationsAwards
W9114F26DA005$45.8K2
States
CategoryPeriod obligationsAwards
Unclassified$45.8K2
Set Asides
CategoryPeriod obligationsAwards
Unclassified$45.8K2

Recent federal awards

Prime contract awards. Select an award to review its history and source evidence.

Award / descriptionAwarding agencyObligationsStart dateEnd date
W9114F26FA027CLINICAL CHEMISTRY COST PER REPORTABLE RESULTDepartment of Defense$3.4KJan 2, 2026Feb 28, 2026
HT940626FE026CLINICAL CHEMISTRY COST PER REPORTABLE RESULTDepartment of Defense$42.4KMar 1, 2026Sep 30, 2026
Explore, filter and export all awards →SubcontractsGrants & subgrants

Registration, certifications & contacts

Registration evidenceDate
SAM updatedOct 28, 2025
Source loadedSep 26, 2026
Initial registrationMar 18, 2010
Entity startSep 27, 1990
IndustryReported size status
325413 — In-Vitro Diagnostic Substance ManufacturingNot reported
ContactRolePublished contact methodsEvidenceSource date
NOEMI MARIA BRAMBILLAGovernment businessContact method not publishedSAM registrationNot available
NOEMI MARIA BRAMBILLAAlternate government businessContact method not publishedSAM registrationNot available
NOEMI MARIA BRAMBILLAElectronic businessContact method not publishedSAM registrationNot available
Registered industries
  • 325413 — In-Vitro Diagnostic Substance Manufacturing
Registered products and services
  • 6640 — Laboratory Equipment and Supplies

Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source

Related companies worth researching

Explore the customer, work and award-size evidence behind each match.

INSTRUMENTATION LABORATORY JAPAN CO., LTD.

1 shared agency customer(s); Shared work: 325413 — In-Vitro Diagnostic Substance Manufacturing; Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
4 awards

U.S. ARKRAY, INC.

1 shared agency customer(s); Shared work: 325413 — In-Vitro Diagnostic Substance Manufacturing; Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
1 awards

CARDINAL HEALTH 414, LLC

1 shared agency customer(s); Shared work: 325413 — In-Vitro Diagnostic Substance Manufacturing; Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
1 awards

BECTON, DICKINSON AND COMPANY

1 shared agency customer(s); Shared work: 325413 — In-Vitro Diagnostic Substance Manufacturing; Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
2 awards

OXFORD NANOPORE TECHNOLOGIES INC

1 shared agency customer(s); Shared work: 325413 — In-Vitro Diagnostic Substance Manufacturing; Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
1 awards

BECTON, DICKINSON AND COMPANY

1 shared agency customer(s); Shared work: 325413 — In-Vitro Diagnostic Substance Manufacturing; Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
1 awards
Data coverage and methodology

Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.

Disclosed relationships only. Missing records do not establish that a contractor has no partners. Ambiguous parent award identifiers are excluded.

Keep your research moving

Save this company, track changes, and evaluate upcoming work against your targets.

Save to my research Find my fit